WO2022007081A1 - 一种治疗帕金森病的中药复方制剂及其制备方法和应用 - Google Patents
一种治疗帕金森病的中药复方制剂及其制备方法和应用 Download PDFInfo
- Publication number
- WO2022007081A1 WO2022007081A1 PCT/CN2020/106957 CN2020106957W WO2022007081A1 WO 2022007081 A1 WO2022007081 A1 WO 2022007081A1 CN 2020106957 W CN2020106957 W CN 2020106957W WO 2022007081 A1 WO2022007081 A1 WO 2022007081A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- parts
- servings
- chinese medicine
- traditional chinese
- parkinson
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims abstract description 66
- 208000018737 Parkinson disease Diseases 0.000 title claims abstract description 51
- 238000002360 preparation method Methods 0.000 title claims abstract description 39
- 150000001875 compounds Chemical class 0.000 title claims abstract description 34
- 239000000203 mixture Substances 0.000 title abstract description 6
- 238000009472 formulation Methods 0.000 title abstract 4
- 244000020518 Carthamus tinctorius Species 0.000 claims abstract description 19
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims abstract description 19
- 241000305491 Gastrodia elata Species 0.000 claims abstract description 18
- 239000002994 raw material Substances 0.000 claims abstract description 14
- 239000000284 extract Substances 0.000 claims abstract description 3
- 241000427159 Achyranthes Species 0.000 claims description 18
- 244000144730 Amygdalus persica Species 0.000 claims description 18
- 244000241838 Lycium barbarum Species 0.000 claims description 18
- 235000015459 Lycium barbarum Nutrition 0.000 claims description 18
- 235000006040 Prunus persica var persica Nutrition 0.000 claims description 18
- 241000405911 Rehmannia glutinosa Species 0.000 claims description 18
- 241000157352 Uncaria Species 0.000 claims description 18
- 241000132012 Atractylodes Species 0.000 claims description 17
- 241001061264 Astragalus Species 0.000 claims description 16
- 235000006533 astragalus Nutrition 0.000 claims description 16
- 210000004233 talus Anatomy 0.000 claims description 16
- 241000382455 Angelica sinensis Species 0.000 claims description 14
- 239000007788 liquid Substances 0.000 claims description 14
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 241000270295 Serpentes Species 0.000 claims description 9
- 241001530038 Pantherophis obsoletus Species 0.000 claims description 8
- 239000008187 granular material Substances 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 8
- 239000005711 Benzoic acid Substances 0.000 claims description 6
- 235000010233 benzoic acid Nutrition 0.000 claims description 6
- 239000012141 concentrate Substances 0.000 claims description 6
- 239000008367 deionised water Substances 0.000 claims description 6
- 229910021641 deionized water Inorganic materials 0.000 claims description 6
- 239000012535 impurity Substances 0.000 claims description 6
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 6
- 235000010234 sodium benzoate Nutrition 0.000 claims description 6
- 239000004299 sodium benzoate Substances 0.000 claims description 6
- 230000001954 sterilising effect Effects 0.000 claims description 6
- 238000004659 sterilization and disinfection Methods 0.000 claims description 6
- 238000003809 water extraction Methods 0.000 claims description 6
- 239000009396 suanzaoren Substances 0.000 claims description 5
- 239000009636 Huang Qi Substances 0.000 claims description 4
- 235000015468 Lycium chinense Nutrition 0.000 claims description 4
- 235000013399 edible fruits Nutrition 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 3
- 238000005469 granulation Methods 0.000 claims description 3
- 230000003179 granulation Effects 0.000 claims description 3
- 238000004382 potting Methods 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 238000004806 packaging method and process Methods 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 244000126002 Ziziphus vulgaris Species 0.000 claims 4
- 230000007812 deficiency Effects 0.000 abstract description 7
- 238000011161 development Methods 0.000 abstract description 6
- 230000004069 differentiation Effects 0.000 abstract description 3
- 208000011580 syndromic disease Diseases 0.000 abstract description 3
- 210000000582 semen Anatomy 0.000 abstract 2
- 241000266855 Astragalus mongholicus Species 0.000 abstract 1
- 241000501743 Gentiana macrophylla Species 0.000 abstract 1
- 241000270273 Ptyas dhumnades Species 0.000 abstract 1
- 241000157373 Uncaria rhynchophylla Species 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 description 12
- 239000008280 blood Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 210000003734 kidney Anatomy 0.000 description 8
- 241001247821 Ziziphus Species 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 210000003523 substantia nigra Anatomy 0.000 description 5
- 241000125175 Angelica Species 0.000 description 4
- 235000001287 Guettarda speciosa Nutrition 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 206010010774 Constipation Diseases 0.000 description 3
- 206010044565 Tremor Diseases 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000007850 degeneration Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- PLRACCBDVIHHLZ-UHFFFAOYSA-N 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Chemical compound C1N(C)CCC(C=2C=CC=CC=2)=C1 PLRACCBDVIHHLZ-UHFFFAOYSA-N 0.000 description 2
- 101001135571 Mus musculus Tyrosine-protein phosphatase non-receptor type 2 Proteins 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- CJCSPKMFHVPWAR-JTQLQIEISA-N alpha-methyl-L-dopa Chemical group OC(=O)[C@](N)(C)CC1=CC=C(O)C(O)=C1 CJCSPKMFHVPWAR-JTQLQIEISA-N 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000007012 clinical effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 206010000125 Abnormal dreams Diseases 0.000 description 1
- 206010006100 Bradykinesia Diseases 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 240000007049 Juglans regia Species 0.000 description 1
- 235000009496 Juglans regia Nutrition 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 208000002740 Muscle Rigidity Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 210000005064 dopaminergic neuron Anatomy 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 238000012346 open field test Methods 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000010825 rotarod performance test Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 235000020234 walnut Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/58—Reptiles
- A61K35/583—Snakes; Lizards, e.g. chameleons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/36—Caryophyllaceae (Pink family), e.g. babysbreath or soapwort
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/51—Gentianaceae (Gentian family)
- A61K36/515—Gentiana
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/52—Juglandaceae (Walnut family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/64—Orobanchaceae (Broom-rape family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8988—Gastrodia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Definitions
- the invention relates to a traditional Chinese medicine compound preparation for treating Parkinson's disease, a preparation method and application thereof, and belongs to the technical field of biomedicine.
- Parkinson's disease is a chronic neurological disease characterized by degeneration of dopaminergic neurons in the substantia nigra of the substantia nigra, and clinical symptoms of movement disorders and non-motor symptoms, which seriously affect the quality of life of patients.
- the increasing incidence of Parkinson's disease has caused a heavy burden on patients, families and society. Therefore, the development of traditional Chinese medicine preparations for Parkinson's disease is a major demand in today's society, as well as a major demand for people's death and health.
- Levodopa is a routine treatment drug for Parkinson's disease, but long-term use can cause diminishing efficacy and many complications. Therefore, the exploration and development of traditional Chinese medicine for the treatment of Parkinson's disease is the current focus and hotspot in traditional Chinese medicine and clinical medicine, and the social needs are urgent.
- the technical problem to be solved by the present invention is to overcome the defects of the prior art, and to provide a traditional Chinese medicine compound preparation for treating Parkinson's disease and its preparation method and application.
- the combination of development and the overall functional status of the patient put forward the syndrome differentiation and treatment of "the essence is empty and the standard is real".
- the present invention provides a traditional Chinese medicine compound preparation for treating Parkinson's disease, which includes traditional Chinese medicine formula components, and the traditional Chinese medicine formula components include the following raw materials or raw material extracts in parts by mass: 6-15 parts of Uncaria chinensis , 3 to 9 parts of Tianma, 6 to 12 parts of Qinjie, 10 to 20 parts of raw astragalus, 10 to 20 parts of Rehmannia glutinosa, 10 to 20 parts of Achyranthes huai, 10 to 20 parts of wolfberry fruit, 10 to 20 parts of Angelica sinensis, fried Atractylodes 10-20 servings, 6-15 servings of fried sour jujube kernels, 3-12 servings of peach kernels, 3-9 servings of safflower, and 20-30 servings of black snake.
- the traditional Chinese medicine formula components include the following raw materials or raw material extracts in parts by mass: 6-15 parts of Uncaria chinensis , 3 to 9 parts of Tianma,
- the components of the traditional Chinese medicine formula include the following components in parts by mass: 12 parts of Uncaria, 6 parts of Gastrodia elata, 6 parts of Qinjie, 10 parts of raw Astragalus, 15 parts of Rehmannia glutinosa, 10 parts of Achyranthes and 10 parts of Lycium barbarum 10 servings of Angelica sinensis, 10 servings of fried Atractylodes, 6 servings of fried sour jujube kernels, 3 servings of peach kernels, 3 servings of safflower, and 20 servings of Wushao snake.
- the components of the traditional Chinese medicine formula include the following components in parts by mass: 6 parts of Uncaria, 9 parts of Gastrodia elata, 10 parts of Qinjie, 15 parts of raw Astragalus, 20 parts of Rehmannia glutinosa, 20 parts of Achyranthes and 15 parts of Lycium barbarum 20 servings of Angelica sinensis, 15 servings of fried Atractylodes, 15 servings of fried Suanzaoren, 12 servings of peach kernels, 9 servings of safflower, and 25 servings of Wushao snake.
- the components of the traditional Chinese medicine formula include the following components in parts by mass: 15 parts of Uncaria, 3 parts of Gastrodia elata, 12 parts of Qinhuang, 20 parts of raw Astragalus, 10 parts of Rehmannia glutinosa, 16 parts of Achyranthes huai, 20 parts of Lycium barbarum 15 servings of Angelica sinensis, 20 servings of fried Atractylodes, 10 servings of fried Suanzaoren, 10 servings of peach kernels, 7 servings of safflower, and 30 servings of Wushao snake.
- the compound preparation includes an effective dose of the traditional Chinese medicine formula components and pharmaceutically acceptable excipients.
- the dosage form of the traditional Chinese medicine compound preparation for treating Parkinson's disease is one of oral liquid, granules, granules and tablets.
- the present invention also provides a preparation method of a traditional Chinese medicine compound preparation oral liquid for treating Parkinson's disease, comprising:
- the present invention also provides a preparation method of traditional Chinese medicine compound preparation granules for treating Parkinson's disease, comprising:
- the present invention also provides the application of the above-mentioned traditional Chinese medicine compound preparation for treating Parkinson's disease in the preparation of a medicine for preventing and/or treating Parkinson's disease.
- This prescription's monarch medicine Uncaria, Gastrodia elata, Qinjie; minister medicine: raw Astragalus, Rehmannia glutinosa, Achyranthes huai, Lycium barbarum, fried Suanzaoren; Adjuvant: Angelica, fried Atractylodes, peach kernel, safflower; Use medicine: Wushao snake.
- the functions of this recipe are: nourishing deficiency and benefiting the brain, nourishing blood and nourishing liver and kidney, quenching wind and calming the mind; nourishing nerves, improving muscle stiffness and tremor.
- composition of this prescription is novel, and it is based on traditional medicinal materials, aiming at the modern pathological mechanism of Parkinson's disease to form a unique drug formula composition;
- the innovative point of the efficacy of this prescription is to differentiate and treat Parkinson's motor symptoms and non-motor symptoms.
- motor symptoms such as bradykinesia, tremor, and muscle rigidity
- Uncaria, Gastrodia elata, and Qinjie are used in this recipe to suppress wind and stop spasm, eliminate stiffness and defibrillate
- non-motor symptoms daily activities, insomnia, vivid dreams, constipation , emotional health and other obstacles
- this recipe uses Rehmannia glutinosa, Achyranthes, Astragalus, Lycium barbarum, yin and blood, liver and kidney, improve non-motor symptoms;
- Parkinson's disease is a degeneration of the nervous system.
- Traditional Chinese medicine believes that the disease is due to deficiency of both liver and kidney, with less qi and blood.
- the kidney stores the essence, also known as true yin, the kidney generates bone, generates marrow and fills the brain, and the liver controls the storage of blood.
- the essence of the deficiency is the real"
- the deficiency is the deficiency of liver and kidney qi and blood, and the actual is wind, fire, phlegm and blood stasis.
- Tonifying the liver and nourishing the kidney can fundamentally improve the occurrence and development of Parkinson's disease. On the basis of nourishing the liver and nourishing the kidney, it can achieve the function of eliminating stiffness and defibrillation when combined with anti-wind and antispasmodic drugs;
- This recipe also innovatively uses astragalus for tonifying qi and blood, angelica and safflower for nourishing blood and dredging collaterals, and walnut kernel for promoting blood circulation and promoting blood circulation. Strengthen the spleen and improve the general symptoms of patients. Constipation is also a common clinical symptom of Parkinson's disease; this recipe uses jujube kernels and peach kernels to achieve a laxative effect.
- this prescription is based on the combination of multi-level, multi-target, occurrence and development of Parkinson's disease, and the overall functional status of the patient, and proposes a syndrome differentiation and treatment of "the deficiency of the essence". Not only has the theoretical basis of modern science, but also received good clinical results, significantly improving the quality of life of patients.
- Embodiment 1 a kind of preparation of traditional Chinese medicine compound oral liquid for the treatment of Parkinson's disease
- the raw material formulas are as follows: 12 parts of Uncaria, 6 parts of Gastrodia elata, 6 parts of Radix Chinensis, 10 parts of raw Astragalus, 15 parts of Rehmannia glutinosa, 10 parts of Achyranthes, 10 parts of Lycium barbarum, 6 parts of fried Suan Zao Ren, 10 parts of angelica, 10 parts of fried Atractylodes, 3 parts of peach kernel, 3 parts of safflower, 20 parts of black snake.
- Embodiment 2 a kind of preparation of traditional Chinese medicine compound oral liquid for the treatment of Parkinson's disease
- the raw material formula is as follows: 6 parts of Uncaria, 9 parts of Gastrodia elata, 10 parts of Qinjie, 15 parts of raw Astragalus, 20 parts of Rehmannia glutinosa, 20 parts of Achyranthes, 15 parts of Lycium barbarum, 20 parts of Angelica sinensis, fried Atractylodes 15 servings, 15 servings of fried sour jujube kernels, 12 servings of peach kernels, 9 servings of safflower, and 25 servings of Wushao snake.
- the preparation method is the same as that of Example 1.
- Embodiment 3 a kind of preparation of traditional Chinese medicine compound granules for the treatment of Parkinson's disease
- the raw material formulas are as follows: 12 parts of Uncaria, 6 parts of Gastrodia elata, 6 parts of Radix Chinensis, 10 parts of raw Astragalus, 15 parts of Rehmannia glutinosa, 10 parts of Achyranthes, 10 parts of Lycium barbarum, 6 parts of fried Suan Zao Ren, 10 parts of angelica, 10 parts of fried Atractylodes, 3 parts of peach kernel, 3 parts of safflower, 20 parts of black snake.
- Embodiment 4 a kind of preparation of traditional Chinese medicine compound granules for the treatment of Parkinson's disease
- the raw material formulas are as follows: 15 parts of Uncaria, 3 parts of Gastrodia elata, 12 parts of Radix Astragali, 20 parts of raw Astragalus, 10 parts of Rehmannia glutinosa, 16 parts of Achyranthes huai, 20 parts of Lycium barbarum, 15 parts of Angelica sinensis, fried Atractylodes 20 servings, 10 servings of fried sour jujube kernels, 10 servings of peach kernels, 7 servings of safflower, and 30 servings of Wushao snake.
- the preparation method is the same as that of Example 3.
- Example 5 Therapeutic effect of a traditional Chinese medicine compound oral liquid for the treatment of Parkinson's disease on Parkinson's disease model mice
- mice were randomly divided into negative group, model group, Madopar group, and traditional Chinese medicine group (the traditional Chinese medicine compound oral liquid prepared in Example 1), with 20 mice in each group. The mice were reared for 5 days to adapt to the environment, during which the mice were trained 3 times in behavioral studies. Modeling and administration, behavioral testing, rotarod test, open field test, morphological testing, high performance liquid chromatography testing, and statistical analysis.
- results of the rotarod experiment showed that the time of rotarod in the model group, Madopar group, and Chinese medicine group was significantly reduced (P ⁇ 0.01) after modeling compared with the negative group (P ⁇ 0.01). Compared with the two groups, the time of rotarod was still significantly decreased (P ⁇ 0.01), and the rotarod time of the Medopa group and the Chinese medicine group was significantly increased compared with the model group at the same period (P ⁇ 0.01). Compared with the negative group, the Madopa group and the traditional Chinese medicine group, the distance of movement was significantly reduced (P ⁇ 0.01), and the time of rest was significantly prolonged (P ⁇ 0.01).
- Morphological detection and immunohistochemical staining results showed that the number of substantia nigra neurons in the traditional Chinese medicine group was significantly higher than that in the model group and Madopar group at 1 week of administration (P ⁇ 0.01); after 2 weeks of administration, the number of substantia nigra Compared with the model group and the Madopar group, the number of neurons increased significantly (P ⁇ 0.01, P ⁇ 0.05).
- Embodiment 6 A kind of traditional Chinese medicine compound oral liquid for the treatment of Parkinson's disease to improve the clinical symptoms of Parkinson's disease patients.
- Application research A kind of traditional Chinese medicine compound oral liquid for the treatment of Parkinson's disease to improve the clinical symptoms of Parkinson's disease patients.
- METHODS Three typical elderly Parkinson's cases (aged 75-90 years old; course of disease 4-10 years, maintained by long-term administration of dopasehydrazine, YAHR grade 4-5) were selected; they took traditional Chinese medicine compound oral liquid for the treatment of Parkinson's disease. (28 days is a course of treatment, and the second course of treatment is carried out after 2 to 4 weeks, and the course is repeated for 2 to 5 courses); the improvement of clinical symptoms and the reduction of dopasehydrazine are observed.
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
一种治疗帕金森病的中药复方制剂及其制备方法和应用，中药复方制剂包括中药配方组分，所述中药配方组分包括以下质量份数的原料或原料提取物：钩藤6～15份、天麻3～9份、秦艽6～12份、生黄芪10～20份、熟地黄10～20份、怀牛膝10～20份、枸杞子10～20份、当归10～20份、炒白术10～20份、炒酸枣仁6～15份、桃仁3～12份、红花3～9份、乌梢蛇20～30份。该复方制剂是从多层面、多靶点、帕金森病的发生与发展、患者整体机能状况结合提出"本虚标实"的辨证施治，不仅具有现代科学的理论基础，而且收到良好的临床效果，明显地改善患者的生活质量。
Description
本发明涉及一种治疗帕金森病的中药复方制剂及其制备方法和应用，属于生物医药技术领域。
帕金森病(Parkinson’s disease,PD)是以中脑黑质多巴胺能神经元退行性变为特征，临床出现运动障碍症状与非运动症状的神经系统慢性疾病，严重影响患者生活质量，随着我国老龄化问题的日益显现，帕金森病的发病率呈持续上升趋势，对患者、家庭和社会造成了沉重的负担。因此，研发针对帕金森病的中药制剂是当今社会的重大需求，也是民生健康的重大需求。左旋多巴是帕金森病常规治疗药物，但长期应用可引起疗效递减及诸多并发症。因此，探索和研制中药治疗帕金森病是目前中药学和临床医学中的重点与热点，社会需求迫切。
发明内容
本发明所要解决的技术问题是克服现有技术的缺陷，提供一种治疗帕金森病的中药复方制剂及其制备方法和应用，本方剂是从多层面、多靶点、帕金森病的发生与发展、患者整体机能状况结合提出“本虚标实”的辨证施治，不仅具有现代科学的理论基础，而且收到良好的临床效果，明显地改善患者的生活质量。
为解决上述技术问题，本发明提供一种治疗帕金森病的中药复方制剂，包括中药配方组分，所述中药配方组分包括以下质量份数的原料或原料提取物：钩藤6～15份、天麻3～9份、秦艽6～12份、生黄芪10～20份、熟地黄10～20份、怀牛膝10～20份、枸杞子10～20份、当归10～20份、炒白术10～20份、炒酸枣仁6～15份、桃仁3～12份、红花3～9份、乌梢蛇20～30份。
优选地，所述中药配方组分包括以下质量份数的组分：钩藤12份、天麻6份、秦艽6份、生黄芪10份、熟地黄15份、怀牛膝10份、枸杞子10份、当归10份、炒白术10份、炒酸枣仁6份、桃仁3份、红花3份、乌梢蛇20份。
优选地，所述中药配方组分包括以下质量份数的组分：钩藤6份、天麻9份、秦艽10份、生黄芪15份、熟地黄20份、怀牛膝20份、枸杞子15份、当归20份、炒白术15份、炒酸枣仁15份、桃仁12份、红花9份、乌梢蛇25份。
优选地，所述中药配方组分包括以下质量份数的组分：钩藤15份、天麻3份、秦艽12 份、生黄芪20份、熟地黄10份、怀牛膝16份、枸杞子20份、当归15份、炒白术20份、炒酸枣仁10份、桃仁10份、红花7份、乌梢蛇30份。
优选地，所述的复方制剂，包括有效剂量的所述的中药配方组分和药学上可接受的辅料。
优选地，治疗帕金森病的中药复方制剂的剂型为口服液、颗粒剂、冲剂、片剂中的一种。
本发明还提供一种治疗帕金森病的中药复方制剂口服液的制备方法，包括：
(1)按照配方比例准备原料：钩藤12份、天麻6份、秦艽6份、生黄芪10份、熟地黄15份、怀牛膝10份、枸杞子10份、当归10份、炒白术10份、炒酸枣仁6份、桃仁3份、红花3份、乌梢蛇20份；水冲洗药材，去杂质；
(2)用去离子水浸泡，25℃，120分钟；
(3)水提，100℃，煎20分钟；
(4)取煎液，4℃，静置12小时，滤过，浓缩，添加苯甲酸或苯甲酸钠；
(5)灌封，灭菌，即得。
本发明还提供一种治疗帕金森病的中药复方制剂颗粒的制备方法，包括：
(1)按照配方比例准备原料：钩藤12份、天麻6份、秦艽6份、生黄芪10份、熟地黄15份、怀牛膝10份、枸杞子10份、当归10份、炒白术10份、炒酸枣仁6份、桃仁3份、红花3份、乌梢蛇20份；水冲洗药材，去杂质；
(2)用去离子水浸泡，25℃，120分钟；
(3)水提，100℃，煎20分钟；
(4)取煎液，4℃，静置12小时，滤过，浓缩，添加苯甲酸或苯甲酸钠；
(5)干燥，制粒，封装，灭菌即得。
本发明还提供上述的治疗帕金森病的中药复方制剂在制备预防和/或治疗帕金森病的药物中的应用。
本方君药：钩藤，天麻，秦艽；臣药：生黄芪，熟地黄，怀牛膝，枸杞子，炒酸枣仁；佐药：当归，炒白术，桃仁，红花；使药：乌梢蛇。
本方功能是：补虚益脑，养血养肝肾，熄风宁神；养护神经，改善肌僵震颤。适用于帕金森病早期，中期症状：纳差，失眠，便秘，嗅觉退变，注意力下降，运动迟缓，肌僵震颤。
本发明所达到的有益效果：
一、本方组成新颖，是在传统药材基础上，针对帕金森病的现代病理机制，形成独特的药物配方组成；
二、本方药物功效的创新点在于，针对帕金森运动症状与非运动症状进行辨证施治。例 如，针对运动症状，运动迟缓、震颤、肌僵直，本方采用钩藤、天麻、秦艽，以达熄风止痉，消僵除颤；针对非运动症状，日常活动、失眠、生动梦境、便秘、情感健康等方面的障碍，本方采用熟地黄、怀牛膝、黄芪、枸杞子，补阴养血、补肝益肾，改善非运动症状；
三，本方辩证施治帕金森病的理论，独特新颖，创新点是从发病的病因着手，帕金森病是神经系统退行性变，中医认为该病属肝肾两虚，气虚血少。肾藏精，又称真阴，肾生骨生髓充脑，肝主藏血，震颤麻痹属肝风内动引起。“本虚标实”，虚为肝肾气血亏虚，实为风、火、痰、瘀。补肝益肾可从根本上改善帕金森病的发生和发展过程，在补肝益肾的基础上结合熄风止痉药物，可达到消僵除颤功能；
四、本方还创新性地使用补气生血的黄芪，养血通络的当归和红花，以及行血活血的核桃仁，四者配伍，功效相助，气足血旺，脉络畅通，养心健脾，改善患者一般症状。便秘也是帕金森病的常见临床症状；本方采用酸枣仁，桃仁以达润肠通便效果。
四个方面的创新点集成，发挥协同功效，因此，本方剂是从多层面、多靶点、帕金森病的发生与发展、患者整体机能状况结合提出“本虚标实”的辨证施治，不仅具有现代科学的理论基础，而且收到良好的临床效果，明显地改善患者的生活质量。
下面结合实施例对本发明作进一步描述。以下实施例仅用于更加清楚地说明本发明的技术方案，而不能以此来限制本发明的保护范围。
实施例1：一种治疗帕金森病中药复方口服液制备
按质量份数计，原料配方如下：钩藤12份、天麻6份、秦艽6份、生黄芪10份、熟地黄15份、怀牛膝10份、枸杞子10份、炒酸枣仁6份、当归10份、炒白术10份、桃仁3份、红花3份、乌梢蛇20份。
制备方法与步骤：
(1)水冲洗药材，去杂质；
(2)用去离子水浸泡，25℃，120分钟；
(3)水提，100℃，煎20分钟；
(4)取煎液，4℃，静置12小时(无菌条件下)，滤过，浓缩，添加苯甲酸或苯甲酸钠；
(5)灌封，灭菌，即得。
实施例2：一种治疗帕金森病中药复方口服液制备
按质量份数计，原料配方如下：钩藤6份、天麻9份、秦艽10份、生黄芪15份、熟地黄20份、怀牛膝20份、枸杞子15份、当归20份、炒白术15份、炒酸枣仁15份、桃仁12 份、红花9份、乌梢蛇25份。
制备方法与实施例1相同。
实施例3：一种治疗帕金森病的中药复方颗粒剂制备
按质量份数计，原料配方如下：钩藤12份、天麻6份、秦艽6份、生黄芪10份、熟地黄15份、怀牛膝10份、枸杞子10份、炒酸枣仁6份、当归10份、炒白术10份、桃仁3份、红花3份、乌梢蛇20份。
制备方法与步骤：
(1)水冲洗药材，去杂质；
(2)用去离子水浸泡，25℃，120分钟；
(3)水提，100℃，煎20分钟；
(4)取煎液，4℃，静置12小时(无菌条件下)，滤过，浓缩，添加苯甲酸或苯甲酸钠；
(5)干燥，制粒，封袋，灭菌即得。
实施例4：一种治疗帕金森病的中药复方颗粒剂制备
按质量份数计，原料配方如下：钩藤15份、天麻3份、秦艽12份、生黄芪20份、熟地黄10份、怀牛膝16份、枸杞子20份、当归15份、炒白术20份、炒酸枣仁10份、桃仁10份、红花7份、乌梢蛇30份。
制备方法与实施例3相同。
实施例5：一种治疗帕金森病的中药复方口服液对帕金森病模型小鼠的治疗作用
材料：一种治疗帕金森病的中药复方口服液原液(5.4g/kg)；
造模药物MPTP(20mg/kg)；美多巴(3.75g/kg)；SPF级C57BL/6小鼠。
方法：将80只小鼠随机分为阴性组、模型组、美多芭组、中药组(实施例1制备的中药复方口服液)，每组20只。饲养5天适应环境，期间训练小鼠行为学3次。造模给药，进行行为学检测，转棒实验，旷场实验，形态学检测，高效液相色谱检测，统计学方法分析。
结果：转棒实验结果表明，制模后模型组、美多芭组、中药组与阴性组比较，转棒的时间显著减少(P<0.01)；用药1周和2周时，模型组与阴性组比较；转棒的时间仍显著减少(P<0.01)，美多芭组、中药组比模型组同期的转棒时间显著增加(P<0.01)，旷场实验结果表明，制模后模型组、美多芭组、中药组与阴性组比较，运动的路程显著减少(P<0.01)，静止的时间显著延长(P<0.01)；用药1周和2周时，模型组比阴性组同期的路程显著减少(P<0.01)，静止时间显著延长(P<0.01，P<0.05)，美多芭组、中药组比模型组同期在路程上显著增加(P<0.05，P<0.01)，在静止时间上明显减少(P<0.01)。
形态学检测，免疫组化染色结果，给药1周时，中药组的黑质神经元数目比模型组和美多芭组显著增多(P<0.01)；给药2周时，中药组的黑质神经元较模型组和美多芭组显著增加(P<0.01，P<0.05)。
结果表明：治疗帕金森病的中药复方口服液对MPTP帕金森病模型鼠具有明显的保护作用，可改善帕金森病模型鼠的行为学，也可使帕金森病模型鼠黑质神经元数目增多，提示该重要具有很好的应用前景。
实施例6：一种治疗帕金森病的中药复方口服液改善帕金森病患者临床症状的应用研究
方法：选择典型的老年帕金森病例3例(年龄75～90岁；病程4～10年，长期服用多巴丝肼维持，YAHR分级4～5级)；服用治疗帕金森病的中药复方口服液(28天为一个疗程，间隔2～4周后再进行第二疗程，重复2～5个疗程)；观察患者临床症状改善和多巴丝肼的减量情况。
结果：3例患者在服用中药复方口服液2～5个疗程后，临床症状均获得不同程度的改善，多巴丝肼减量达20％～50％，YAHR分组达2～4级。
结果表明：治疗帕金森病的中药复方口服液对帕金森病人具有良好的临床疗效，临床效果提示该中药复方口服液可对人体帕金森病多靶点调节，并对退行性病变神经进行修复。
以上所述仅是本发明的优选实施方式，应当指出，对于本技术领域的普通技术人员来说，在不脱离本发明技术原理的前提下，还可以做出若干改进和变形，这些改进和变形也应视为本发明的保护范围。
Claims (9)
- 一种治疗帕金森病的中药复方制剂，其特征在于，包括中药配方组分，所述中药配方组分包括以下质量份数的原料或原料提取物：钩藤6～15份、天麻3～9份、秦艽6～12份、生黄芪10～20份、熟地黄10～20份、怀牛膝10～20份、枸杞子10～20份、当归10～20份、炒白术10～20份、炒酸枣仁6～15份、桃仁3～12份、红花3～9份、乌梢蛇20～30份。
- 根据权利要求1所述的治疗帕金森病的中药复方制剂，其特征在于，所述中药配方组分包括以下质量份数的组分：钩藤12份、天麻6份、秦艽6份、生黄芪10份、熟地黄15份、怀牛膝10份、枸杞子10份、当归10份、炒白术10份、炒酸枣仁6份、桃仁3份、红花3份、乌梢蛇20份。
- 根据权利要求1所述的治疗帕金森病的中药复方制剂，其特征在于，所述中药配方组分包括以下质量份数的组分：钩藤6份、天麻9份、秦艽10份、生黄芪15份、熟地黄20份、怀牛膝20份、枸杞子15份、当归20份、炒白术15份、炒酸枣仁15份、桃仁12份、红花9份、乌梢蛇25份。
- 根据权利要求1所述的治疗帕金森病的中药复方制剂，其特征在于，所述中药配方组分包括以下质量份数的组分：钩藤15份、天麻3份、秦艽12份、生黄芪20份、熟地黄10份、怀牛膝16份、枸杞子20份、当归15份、炒白术20份、炒酸枣仁10份、桃仁10份、红花7份、乌梢蛇30份。
- 根据权利要求1-4任意一项所述的治疗帕金森病的中药复方制剂，其特征在于，包括有效剂量的所述的中药配方组分和药学上可接受的辅料。
- 根据权利要求5所述的治疗帕金森病的中药复方制剂，其特征在于，治疗帕金森病的中药复方制剂的剂型为口服液、颗粒剂、冲剂、片剂中的一种。
- 一种治疗帕金森病的中药复方制剂口服液的制备方法，其特征在于，包括：(1)按照配方比例准备原料：钩藤12份、天麻6份、秦艽6份、生黄芪10份、熟地黄15份、怀牛膝10份、枸杞子10份、当归10份、炒白术10份、炒酸枣仁6份、桃仁3份、红花3份、乌梢蛇20份；水冲洗药材，去杂质；(2)用去离子水浸泡，25℃，120分钟；(3)水提，100℃，煎20分钟；(4)取煎液，4℃，静置12小时，滤过，浓缩，添加苯甲酸或苯甲酸钠；(5)灌封，灭菌，即得。
- 一种治疗帕金森病的中药复方制剂颗粒的制备方法，其特征在于，包括：(1)按照配方比例准备原料：钩藤12份、天麻6份、秦艽6份、生黄芪10份、熟地黄15份、怀牛膝10份、枸杞子10份、当归10份、炒白术10份、炒酸枣仁6份、桃仁3份、红花3份、乌梢蛇20份；水冲洗药材，去杂质；(2)用去离子水浸泡，25℃，120分钟；(3)水提，100℃，煎20分钟；(4)取煎液，4℃，静置12小时，滤过，浓缩，添加苯甲酸或苯甲酸钠；(5)干燥，制粒，封装，灭菌即得。
- 权利要求1-4任一项所述的治疗帕金森病的中药复方制剂在制备预防和/或治疗帕金森病的药物中的应用。
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020227034320A KR20220160599A (ko) | 2020-07-10 | 2020-08-05 | 파킨슨병을 치료하는 중국 한방약 복합제제 및 이의 제조 방법과 응용 |
| US17/996,076 US20230210936A1 (en) | 2020-07-10 | 2020-08-05 | Traditional chinese medicine compound preparation for treating parkinson's disease and its preparation method and application |
| JP2022562037A JP7460204B2 (ja) | 2020-07-10 | 2020-08-05 | パーキンソン病を治療するための複方漢方製剤及びその製造方法並びに使用 |
| EP20943895.1A EP4180053A4 (en) | 2020-07-10 | 2020-08-05 | FORMULATION OF A COMPOUND OF TRADITIONAL CHINESE MEDICINE FOR THE TREATMENT OF PARKINSON'S DISEASE, PROCESS OF PRODUCTION THEREOF AND USE THEREOF |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010661407.4A CN111686209A (zh) | 2020-07-10 | 2020-07-10 | 一种治疗帕金森病的中药复方制剂及其制备方法和应用 |
| CN202010661407.4 | 2020-07-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2022007081A1 true WO2022007081A1 (zh) | 2022-01-13 |
Family
ID=72485782
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CN2020/106957 WO2022007081A1 (zh) | 2020-07-10 | 2020-08-05 | 一种治疗帕金森病的中药复方制剂及其制备方法和应用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230210936A1 (zh) |
| EP (1) | EP4180053A4 (zh) |
| JP (1) | JP7460204B2 (zh) |
| KR (1) | KR20220160599A (zh) |
| CN (1) | CN111686209A (zh) |
| WO (1) | WO2022007081A1 (zh) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115429863B (zh) * | 2022-09-01 | 2023-10-13 | 河南大学第一附属医院 | 一种治疗帕金森相关的非运动症状的中药组合物 |
| CN116726138B (zh) * | 2023-08-11 | 2023-11-24 | 中国人民解放军总医院第六医学中心 | 一种治疗老年帕金森病及并发症的中药组合物及其制备方法及应用 |
| CN117442687A (zh) * | 2023-11-13 | 2024-01-26 | 沈阳君弘医药科技有限公司 | 治疗帕金森病的中药组合物及其应用 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101269188A (zh) * | 2008-05-15 | 2008-09-24 | 天科仁祥技术（北京）有限责任公司 | 一种治疗帕金森病的中药组合及其制备方法 |
| CN102872348A (zh) * | 2011-07-14 | 2013-01-16 | 张仲辉 | 一种治疗气血两虚所致震颤麻痹的中药方 |
| CN103127399A (zh) * | 2013-02-03 | 2013-06-05 | 李振光 | 治疗帕金森病的中药汤剂 |
| CN104721687A (zh) * | 2013-12-19 | 2015-06-24 | 上官瑞红 | 一种治疗帕金森综合症的中药汤剂 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20050021026A (ko) | 2001-06-15 | 2005-03-07 | 주식회사 장생도라지 | 장생도라지 추출물을 포함하는 면역계의 이상으로부터발생하는 질병의 예방 및 치료용 약제학적 조성물 |
| CN105362717A (zh) * | 2015-11-12 | 2016-03-02 | 白晶 | 一种治疗帕金森病的药物 |
| CN111012870A (zh) * | 2018-10-10 | 2020-04-17 | 喻可安 | 平震药 |
-
2020
- 2020-07-10 CN CN202010661407.4A patent/CN111686209A/zh active Pending
- 2020-08-05 US US17/996,076 patent/US20230210936A1/en active Pending
- 2020-08-05 JP JP2022562037A patent/JP7460204B2/ja active Active
- 2020-08-05 EP EP20943895.1A patent/EP4180053A4/en active Pending
- 2020-08-05 KR KR1020227034320A patent/KR20220160599A/ko unknown
- 2020-08-05 WO PCT/CN2020/106957 patent/WO2022007081A1/zh unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101269188A (zh) * | 2008-05-15 | 2008-09-24 | 天科仁祥技术（北京）有限责任公司 | 一种治疗帕金森病的中药组合及其制备方法 |
| CN102872348A (zh) * | 2011-07-14 | 2013-01-16 | 张仲辉 | 一种治疗气血两虚所致震颤麻痹的中药方 |
| CN103127399A (zh) * | 2013-02-03 | 2013-06-05 | 李振光 | 治疗帕金森病的中药汤剂 |
| CN104721687A (zh) * | 2013-12-19 | 2015-06-24 | 上官瑞红 | 一种治疗帕金森综合症的中药汤剂 |
Non-Patent Citations (3)
| Title |
|---|
| MA QIMING, DU LIANPING: "Clinical Observation of 42 Cases of Parkinson's Disease Treated with Integrated Traditional and Western Medicine", CHINESE JOURNAL OF INTEGRATIVE MEDICINE ON CARDIO-/CEREBROVASCULAR DISEASE, vol. 1, no. 10, 31 October 2003 (2003-10-31), pages 614 - 615, XP055887730, ISSN: 1672-1349 * |
| See also references of EP4180053A4 * |
| ZHAO, JIANJUN: "Parkinson's Disease", CLINICAL DIAGNOSIS AND TREATMENT OF NEUROLOGICAL DISEASES, 31 January 2006 (2006-01-31), China, pages 253 - 259, XP009533739, ISBN: 978-7-5023-5185-4 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20230210936A1 (en) | 2023-07-06 |
| CN111686209A (zh) | 2020-09-22 |
| JP7460204B2 (ja) | 2024-04-02 |
| JP2023521405A (ja) | 2023-05-24 |
| EP4180053A1 (en) | 2023-05-17 |
| EP4180053A4 (en) | 2024-01-17 |
| KR20220160599A (ko) | 2022-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2022007081A1 (zh) | 一种治疗帕金森病的中药复方制剂及其制备方法和应用 | |
| WO2022037561A1 (zh) | 一种治疗哮喘病的中药组合物及其应用 | |
| CN103566087A (zh) | 一种治疗认知功能障碍的药物组合物及其在制备阿尔茨海默病药物中的应用 | |
| CN114177251A (zh) | 一种用于防治风湿病的中药组合物、养生酒及其制备方法 | |
| CN101337019A (zh) | 一种治疗带状疱疹后遗神经痛的内服中药的配方及其制备方法 | |
| CN101181383A (zh) | 一种治疗中风的药物组合物及制备方法 | |
| WO2022016827A1 (zh) | 一种神经再生复方制剂及其制备方法和用途 | |
| CN104189781A (zh) | 一种治疗神经胶质瘤的中药组合物 | |
| CN1704113A (zh) | 治疗心脑血管疾病的中药丹红制剂及其制备方法 | |
| CN1692938A (zh) | 一种用于明目的中药复方制剂及其制备方法 | |
| CN1182864C (zh) | 一种治疗血管性痴呆疾病的药物及其制备方法 | |
| CN101129461A (zh) | 一种用于治疗高血压、脑血栓、脑栓塞、冠心病的中药组合物 | |
| CN116211945B (zh) | 一种中药组合物及其制备方法与在制备用于治疗或预防慢性脑供血不足的药物中的应用 | |
| CN116370598B (zh) | 一种中药组合物在化疗神经病理性疼痛中的应用 | |
| CN104013831B (zh) | 一种治疗脑供血不足的药物 | |
| CN116726138B (zh) | 一种治疗老年帕金森病及并发症的中药组合物及其制备方法及应用 | |
| CN109908294B (zh) | 一种用于治疗支气管扩张症稳定期的药物组合物及其制备方法和用途 | |
| CN114588240B (zh) | 一种治疗结直肠癌的中药组合物及其制备方法和应用 | |
| CN115737778B (zh) | 具有调压功效的中药制剂 | |
| CN1031243C (zh) | 治疗白癜风的药物 | |
| CN108635420B (zh) | 一种用于治疗肾炎的中药组合物及其提取物 | |
| CN112717052A (zh) | 用于防治放疗损伤的中药组合物和清血颗粒 | |
| EA044900B1 (ru) | Составной препарат для регенерации нервной ткани и способ его получения и применения | |
| CN1283303C (zh) | 治疗缺血性中风的药物组合物 | |
| CN110833596A (zh) | 一种治疗结节性红斑的中药 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20943895 Country of ref document: EP Kind code of ref document: A1 |
|
| ENP | Entry into the national phase |
Ref document number: 2022562037 Country of ref document: JP Kind code of ref document: A |
|
| ENP | Entry into the national phase |
Ref document number: 2020943895 Country of ref document: EP Effective date: 20230210 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |